Related Experiment Video

Updated: Apr 22, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.1K

A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

Stuart A Ross1

  • 1University of Calgary , Calgary, Alberta , Canada.

Current Medical Research and Opinion
|October 10, 2014
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer significant benefits for type 2 diabetes (T2D) patients. These agents effectively improve glycemic control and aid in weight management, representing a key advance in T2D therapy.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Clinical Trial Design

Background:

  • Current type 2 diabetes (T2D) management guidelines emphasize glycemic control, weight management, and cardiovascular risk factors.
  • Composite endpoints are increasingly utilized in clinical trials to assess the overall efficacy of T2D interventions.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of antihyperglycemic agents with potential benefits beyond glucose lowering.

Purpose of the Study:

  • To evaluate the efficacy of GLP-1 RAs in patients with type 2 diabetes (T2D) who have failed metformin monotherapy.
  • To analyze the impact of GLP-1 RAs on composite endpoints that measure net clinical benefit.
  • To compare the effectiveness of exenatide and liraglutide using various composite endpoints.

Main Methods:

  • Systematic literature search of MEDLINE, Embase, and Google Scholar for studies using composite endpoints.
  • Inclusion of trials reporting outcomes for exenatide and/or liraglutide.
  • Review of bibliographies from relevant articles to identify additional studies.

Main Results:

  • GLP-1 RAs demonstrated superiority over other agents in achieving net clinical benefit for T2D patients on metformin.
  • Common composite endpoints included HbA1c <7%, no weight gain, and no hypoglycemia.
  • Findings were consistent across studies, irrespective of the specific composite endpoint used, highlighting benefits like improved glycemic control and weight maintenance.

Conclusions:

  • Composite endpoints are a valuable tool for assessing T2D interventions, capturing multiple aspects of treatment efficacy.
  • Widely used composite endpoints effectively measure glycemic control, safety, and cardiovascular risk markers.
  • GLP-1 RAs show significant promise in providing comprehensive benefits for T2D patients, aligning with current treatment goals.
Keywords:
Composite endpointsExenatideGLP-1LiraglutideType 2 diabetes

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.2K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
997
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
982
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
937
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K